Hims hair loss review: Cost, how it works, and who it’s good for

A whopping 85% of men experience significantly thinning hair by age 50, and two-thirds experience noticeable hair loss by age ...

Hims expansion may not come in time for risky GLP-1 business

By Amina Niasse NEW YORK, March 2 (Reuters) - Telehealth company Hims & Hers Health, known for its weight-loss drug business, ...

Hims And Hers Retreats On GLP1 Pills As Legal And Regulatory Risks Grow

Hims & Hers Health launched a compounded semaglutide based weight loss pill, then quickly pulled it following legal threats from Novo Nordisk and federal scrutiny. Federal regulators have referred the ...
Seeking Alpha

Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade)

We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans, driving 50% Y/Y revenue growth.
Seeking Alpha

Hims & Hers: Capitalizing On Robust Subscriber/ARPU Growth - Upgraded Buy Rating

HIMS is upgraded to a speculative Buy after the steep correction, with the cheaper valuations offering a much-needed, improved margin of safety. Robust subscription/ARPU growth, international ...
Nasdaq

HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside?

Virtual healthcare platforms are redefining patient access to care, with Hims & Hers Health, Inc. HIMS and GoodRx Holdings, Inc. GDRX among the leaders in this digital shift. HIMS is a consumer-first, ...